By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: 617-236-0535 Fax: 617-249-0490


Start Up

Company News
Zafgen (ZFGN) Granted Orphan Drug Designation In The European Union For Beloranib, A First-In-Class Metap2 Inhibitor For The Treatment Of Prader-Willi Syndrome 7/10/2014 5:55:37 AM
Zafgen (ZFGN) Appoints Patrick Loustau As President 7/1/2014 8:54:41 AM
Zafgen (ZFGN) Appoints New Member Of Board Of Directors 6/27/2014 7:27:45 AM
Zafgen (ZFGN) Announces Closing Of Initial Public Offering And Full Exercise Of Over-Allotment Option 6/25/2014 8:42:25 AM
Zafgen (ZFGN) Announces Pricing of Initial Public Offering 6/19/2014 8:22:23 AM
Massachusett's Zafgen Lines Up $86 Million IPO To Bankroll Obesity Drug Push 4/21/2014 6:56:33 AM
Oxford Finance And Midcap Financial Close $20 Million Senior Credit Facility With Zafgen 4/18/2014 6:32:16 AM
Zafgen Announces Initial Results From Phase 2a Study Of Beloranib In Patients With Prader-Willi Syndrome 1/15/2014 8:05:35 AM
Zafgen To Present At 32nd Annual J.P. Morgan Healthcare Conference 1/9/2014 6:50:43 AM
Zafgen Appoints Chief Commercial Officer And New Member Of Board Of Directors 1/9/2014 6:39:24 AM